title: Coxibs: can this class of drugs survive?
authors.affiliation: Division of Basic Medical Sciences, Faculty of Medicine, Memorial University of Newfoundland, St John's, NL, Canada.
authors.forename: Reza
authors.initials: R
authors.lastname: Tabrizchi
mesh_terms: D001168:Arthritis / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics; D000077613:Etoricoxib; D019317:Evidence-Based Medicine; D006207:Half-Life; D006801:Humans; D007555:Isoxazoles / Q000009:adverse effects; D007783:Lactones / Q000009:adverse effects; D018579:Patient Selection; D011720:Pyrazoles / Q000009:adverse effects; D011725:Pyridines / Q000009:adverse effects; D013449:Sulfonamides / Q000009:adverse effects; D013450:Sulfones / Q000009:adverse effects; D000096926:Benzenesulfonamides
chemical_list: D000068579:Celecoxib; D052246:Cyclooxygenase 2 Inhibitors; D000077613:Etoricoxib; D007555:Isoxazoles; D007783:Lactones; D011720:Pyrazoles; D011725:Pyridines; D013449:Sulfonamides; D013450:Sulfones; C116926:rofecoxib; C406224:valdecoxib; D000096926:Benzenesulfonamides